Listen to this Blog
Q1 FY26 Key Financial Highlights
- Revenue: ₹5,842 crore, up 15% YoY
- EBITDA: ₹852 crore, up 26% YoY (margin 14.6%)
- PAT: ₹433 crore, up 42% YoY
- EPS (Diluted): ₹30.10 (not annualised)
Segment-wise performance
- Healthcare Services: ₹2,935 crore revenue, up 11% YoY | EBITDA margin 24.5% | PAT ₹384 crore, up 17%
- Retail Health & Diagnostics (AHLL): ₹435 crore, up 19% | EBITDA margin 9.3% | PAT loss reduced to ₹8 crore
- Digital Health & Pharmacy (Apollo HealthCo): ₹2,472 crore, up 19% | EBITDA ₹94 crore vs ₹23 crore last year | PAT ₹57 crore, turnaround from loss
Operational & Strategic Updates
- Operating beds: 8,030; occupancy 65%
- Planned bed additions: Bengaluru, Hyderabad, Chennai, Delhi NCR, Patna, Jaipur over 3–4 years — 4,370 beds, ₹7,600 crore investment
- Apollo 24/7 GMV: ₹682 crore, up 23% YoY
- Pharmacy: Significant improvements online and offline
- AI-powered preventive health initiatives: OraLife (oral cancer detection), Apollo Zen (advanced health management)
Stock Market Snapshot (as on result date)
- Previous Close: ₹7,236.60
- 52-Week High / Low: ₹7,717.00 / ₹6,002.15
- Valuation: PE 81.93 | PB 13.52 | ROE 16.50%
- Market Cap: ₹1.10 lakh crore
Industry & Sector Outlook
- Indian healthcare set for double-digit growth driven by insurance penetration, rising middle class, and digital adoption
- Preventive health, diagnostics, and telemedicine expected to accelerate post-2025
Company Outlook & Strategic Moves
- Growth focus: Tier-2 & Tier-3 markets with “Care-Within-Reach” programs
- Strategic demerger: Pharmacy and digital businesses planned to unlock shareholder value by FY27
- Sustainability targets: 20% reduction in energy use per patient day; eco-friendly hospital construction
Impact & Long-Term Themes
- Sector strength reinforced by Apollo’s 15% revenue and 42% PAT growth
- Bed capacity expansion of 4,300+ and ₹7,600 crore investment signal rising demand
- Growth across services, diagnostics, and digital health; AI/telemedicine adoption rising
- Long-term trajectory includes double-digit revenue growth, asset expansion, and scalable digital platforms
- Disclosure
- This update is informational and not investment advice. Conduct your own due diligence.
Q1 FY26 Key Financial Highlights
- Revenue: ₹5,842 crore, up 15% YoY
- EBITDA: ₹852 crore, up 26% YoY (margin 14.6%)
- PAT: ₹433 crore, up 42% YoY
- EPS (Diluted): ₹30.10 (not annualised)
Segment-wise performance
- Healthcare Services: ₹2,935 crore revenue, up 11% YoY | EBITDA margin 24.5% | PAT ₹384 crore, up 17%
- Retail Health & Diagnostics (AHLL): ₹435 crore, up 19% | EBITDA margin 9.3% | PAT loss reduced to ₹8 crore
- Digital Health & Pharmacy (Apollo HealthCo): ₹2,472 crore, up 19% | EBITDA ₹94 crore vs ₹23 crore last year | PAT ₹57 crore, turnaround from loss
Operational & Strategic Updates
- Operating beds: 8,030; occupancy 65%
- Planned bed additions: Bengaluru, Hyderabad, Chennai, Delhi NCR, Patna, Jaipur over 3–4 years — 4,370 beds, ₹7,600 crore investment
- Apollo 24/7 GMV: ₹682 crore, up 23% YoY
- Pharmacy: Significant improvements online and offline
- AI-powered preventive health initiatives: OraLife (oral cancer detection), Apollo Zen (advanced health management)
Stock Market Snapshot (as on result date)
- Previous Close: ₹7,236.60
- 52-Week High / Low: ₹7,717.00 / ₹6,002.15
- Valuation: PE 81.93 | PB 13.52 | ROE 16.50%
- Market Cap: ₹1.10 lakh crore
Industry & Sector Outlook
- Indian healthcare set for double-digit growth driven by insurance penetration, rising middle class, and digital adoption
- Preventive health, diagnostics, and telemedicine expected to accelerate post-2025
Company Outlook & Strategic Moves
- Growth focus: Tier-2 & Tier-3 markets with “Care-Within-Reach” programs
- Strategic demerger: Pharmacy and digital businesses planned to unlock shareholder value by FY27
- Sustainability targets: 20% reduction in energy use per patient day; eco-friendly hospital construction
Impact & Long-Term Themes
- Sector strength reinforced by Apollo’s 15% revenue and 42% PAT growth
- Bed capacity expansion of 4,300+ and ₹7,600 crore investment signal rising demand
- Growth across services, diagnostics, and digital health; AI/telemedicine adoption rising
- Long-term trajectory includes double-digit revenue growth, asset expansion, and scalable digital platforms
- Disclosure
- This update is informational and not investment advice. Conduct your own due diligence.
.jpg)
